Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.
Indiana Clinical Research Center, Indianapolis, Indiana, United States
Purdue University, Indianapolis, Indiana, United States
Indiana University, Indianapolis, Indiana, United States
Indiana University, Indianapolis, Indiana, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Indiana University, Indianapolis, Indiana, United States
Indiana Clinical Research Center, Indianapolis, Indiana, United States
Purdue University, Indianapolis, Indiana, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Regional Cardiology Associates, Sacramento, California, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.